Carl Schotborgh, MD

Paclitaxel DCB 12-Month PREVAIL Study Results Figure 1

Original Contribution

Paclitaxel Drug-Coated Balloon for the Treatment of De Novo Small-Vessel and Restenotic Coronary Artery Lesions: 12-Month Results of the Prospective, Multicenter, Single-Arm PREVAIL Study

11/01/2021

Cheryl Shen , MS;

Gwenn Wetzels , PhD;

Luca Testa , MD, PhD;

Joseph "Jo" Dens , MD, PhD;

Mark S. Patterson , MBBS, PhD, MD, MRCP;

Azeem Latib , MD, BCh, MBBCh;

Patrizio Lancellotti , MD, PhD;

Pierfrancesco Agostoni , MD, PhD;

Frankie C.C. Tam , MD;

Carl Schotborgh , MD;

Elvin Kedhi , MD;

Pieter R. Stella , MD, PhD;

The PREVAIL study evaluated the safety and effectiveness of a paclitaxel DCB for the treatment of coronary de novo and ISR lesions in patients with symptomatic ischemic heart disease.

The PREVAIL study evaluated the...

11/01/2021

Journal of Invasive Cardiology

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8

November 8 ⁠–⁠ November 10

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Carl Schotborgh, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products